OTC Markets OTCQB - Delayed Quote USD

Nuo Therapeutics, Inc. (AURX)

1.5200
0.0000
(0.00%)
At close: May 19 at 9:31:52 AM EDT
Loading Chart for AURX
  • Previous Close 1.5200
  • Open 1.5200
  • Bid 1.5000 x 40000
  • Ask 1.5200 x 40000
  • Day's Range 1.5200 - 1.5200
  • 52 Week Range 0.2520 - 1.9300
  • Volume 4,000
  • Avg. Volume 8,536
  • Market Cap (intraday) 71.166M
  • Beta (5Y Monthly) -931.28
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0500
  • Earnings Date Aug 11, 2025 - Aug 15, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Nuo Therapeutics, Inc. operates as a regenerative therapies company that develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. The company offers the Aurix System, which separates autologous blood to produce a platelet-based therapy for the chronic wound care market. It serves hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was incorporated in 1998 and is based in Houston, Texas.

www.nuot.com

9

Full Time Employees

December 31

Fiscal Year Ends

Recent News: AURX

View More

Performance Overview: AURX

Trailing total returns as of 5/20/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

AURX
8.57%
S&P 500 (^GSPC)
1.00%

1-Year Return

AURX
102.67%
S&P 500 (^GSPC)
11.91%

3-Year Return

AURX
43.40%
S&P 500 (^GSPC)
52.27%

5-Year Return

AURX
2,391.80%
S&P 500 (^GSPC)
99.91%

Compare To: AURX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AURX

View More

Valuation Measures

Annual
As of 5/19/2025
  • Market Cap

    71.17M

  • Enterprise Value

    71.26M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    43.36

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    44.12

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -146.20%

  • Return on Assets (ttm)

    -130.45%

  • Return on Equity (ttm)

    -3,922.86%

  • Revenue (ttm)

    1.61M

  • Net Income Avi to Common (ttm)

    -2.36M

  • Diluted EPS (ttm)

    -0.0500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    55.66k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -1.19M

Research Analysis: AURX

View More

Company Insights: AURX

Research Reports: AURX

View More

People Also Watch